Drugs / CJM112
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03111992 | Dec 2017 → Mar 2020 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02900664 | Aug 2016 → Mar 2021 | colorectal cancer, non-small cell lung carcinoma, triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01828086 | Jun 2013 → Oct 2015 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03299686 | Nov 2017 → Apr 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02998671 | Dec 2016 → Aug 2018 | acne | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02421172 | Apr 2015 → Nov 2016 | hidradenitis suppurativa | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CJM112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02421172 ↗ |
| Modality | Monoclonal antibody | “CJM112 Fully human IgG1 monoclonal antibody” NCT02421172 ↗ |
| Route | Subcutaneous | “Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses” NCT02421172 ↗ |
| Target | IL17A | “Interleukin 17A binding agent” CHEMBL4297926 ↗ |